best real peptides FAQ

P21 eliminates the gp130 inflammatory pathway that complicates Semax studies. Long-term potentiation (LTP) measurements in hippocampal slices show that P21 enhances NMDA receptor-mediated currents without altering baseline microglial activation markers (Iba1, CD68). A critical distinction when studying synaptic mechanisms independent of neuroinflammation. Dose at 1 mg/kg twice daily; the short half-life requires morning and evening administration to maintain steady-state receptor occupancy, but this avoids the trough-peak oscillations that distort electrophysiology data in single-dose protocols.

Avoid GHRP-6 and GHRP-2 entirely. Both activate CD36 scavenger receptors and produce significant ghrelin signaling. CJC-1295/Ipamorelin is the cleanest stack in 2026: Ipamorelin selectively hits GHS-R1a without cortisol or prolactin release, and CJC-1295 works through GHRH pathways with zero ghrelin involvement. This eliminates lipid metabolism confounds (from CD36) and appetite variables (from ghrelin) that corrupt data in body composition studies.

Switch to CJC-1295 DAC with Ipamorelin. Ipamorelin produces less than 10% appetite stimulation in research populations, and CJC-1295 (a GHRH analog) has no ghrelin activity. This combination isolates GH-mediated effects without hunger confounds, making it the standard for metabolic research in 2026. Dose CJC at 1–2mg weekly and Ipamorelin at 200–300 mcg per injection.

Cerebrolysin's peptide cocktail covers pathways Semax cannot touch. It delivers trophic factor-like activity across BDNF, GDNF, and NGF systems simultaneously, producing neuroprotection in ischemic stroke, traumatic brain injury, and neurodegenerative models. The broad mechanism means you can't isolate which pathway drives a given effect, but that's acceptable in screening studies where the goal is identifying protective compounds before mechanistic dissection. Administer 2.5–5 mL daily for 10–20 days; the higher volume requires intramuscular rather than subcutaneous injection to avoid tissue saturation.

Use Hexarelin at the same three-times-daily schedule GHRP-6 required, but reduce the dose to 50–75 mcg per injection (versus GHRP-6's typical 100–200 mcg). Hexarelin's higher receptor affinity means you'll still achieve equivalent or superior GH release while maintaining identical dosing intervals. This approach works for studies designed to match historical GHRP-6 protocols while upgrading to a more potent compound.

Dihexa is the correct choice. Initial cognitive effects appear within 6–12 hours post-administration in rodent behavioral assays, and the synaptic remodeling effect persists 14–21 days. Far longer than Semax's 48-hour window. The trade-off is lower peak plasma concentration compared to Semax's rapid intranasal spike, but the area-under-curve (AUC) over 24 hours is 3–4× higher, meaning more total receptor engagement despite slower onset. Use 5 mg/kg subcutaneous once daily; effects plateau after 7 consecutive days, so cycling protocols (7 days on, 7 days off) prevent receptor downregulation.

Use MK-677 as an oral alternative. It's the only ghrelin mimetic that doesn't require subcutaneous injection, and its 24-hour half-life allows once-daily dosing with flexible timing. Dose at 12.5–25mg daily, administered in the evening to align with natural GH secretion rhythms. The limitation: oral bioavailability (~60–70%) introduces more dose-to-effect variability than injectable peptides, so plan for slightly wider confidence intervals in GH measurement endpoints.

Use Hexarelin at 150–200 mcg twice daily. It binds GHS-R1a with higher affinity than any other injectable secretagogue, producing GH pulses 3–4× larger than equivalent GHRP-6 doses. The trade-off is receptor desensitization. Continuous Hexarelin use beyond 8–12 weeks can blunt GH response, so most protocols cycle it (4–6 weeks on, 2–4 weeks off) or rotate it with Ipamorelin to preserve receptor sensitivity.

It depends on the compound and your institutional setting. Survodutide and mazdutide are available through FDA-registered 503B compounding facilities like Real Peptides, which prepare peptides under USP standards for research use. Retatrutide is investigational-only. Access requires enrollment in a pharmaceutical company's sponsored clinical trial, which limits availability to approved research sites. If your protocol allows compounded peptides, survodutide and mazdutide offer dual-pathway engagement without the access restrictions of investigational-only compounds.

Yes. Tirzepatide's dual GLP-1/GIP mechanism produces higher rates of gastrointestinal adverse events during dose escalation than cagrilintide. SURMOUNT-1 reported nausea in 31% of tirzepatide patients versus 18% in the cagrilintide arm of the REWIND trial. The difference is GLP-1 receptor density in the gut. Higher activation slows gastric emptying more aggressively, which amplifies nausea but also produces greater weight loss. Titrating slowly (4-week intervals between dose increases) allows GLP-1 receptor downregulation to catch up with dose, reducing discontinuation rates.

Yes. Tirzepatide, retatrutide, survodutide, and mazdutide all have half-lives of 5–7 days, making them compatible with weekly subcutaneous injection protocols. Cagrilintide itself requires weekly dosing (2.4mg standard), so transitioning to any of these alternatives maintains the same administration schedule. The pharmacokinetic difference is receptor engagement, not dosing frequency. Dual and triple agonists achieve higher plasma concentrations of active peptide at therapeutic doses, which is why their clinical endpoints exceed cagrilintide despite similar injection intervals.